Immutep

Immutep is a biotechnology company dedicated to developing novel immunotherapies for cancer and autoimmune diseases, with operations in Europe, Australia, and the United States. Immutep is committed to leveraging its existing technology and expertise to develop innovative treatment options for patients. Immutep's leading product pipeline is based on the LAG-3 immune control mechanism, which plays a crucial role in the regulation of T-cell immune responses. The most clinically advanced product is T-cell immune stimulant (APC activator) IMP321, used in cancer chemo-immunotherapy, which has completed early Phase II trials.